Bio-Rad Laboratories 2024年第四季度每股收益 $2.90 超过预期 $2.86，销售额 $6.675亿 未达预期 $6.793亿
Bio-Rad Laboratories（纽约证券交易所代码：BIO）报告季度每股收益为 $2.90，高于分析师一致预期的 $2.86，增幅为 1.4%。 与去年同期的每股收益 $3.10 相比，下降了 6.45%。公司报告季度销售额为 $6.675亿，低于分析师一致预期的 $6.793亿，减少了 1.74%。 与去年同期的销售额 $6.8118亿 相比，减少了 2.01%。
以上内容来自Benzinga Earnings专栏，原文如下：
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.90 per share which beat the analyst consensus estimate of $2.86 by 1.4 percent. This is a 6.45 percent decrease over earnings of $3.10 per share from the same period last year. The company reported quarterly sales of $667.50 million which missed the analyst consensus estimate of $679.30 million by 1.74 percent. This is a 2.01 percent decrease over sales of $681.18 million the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available